Bibliografías temáticas / Progressive systemic sclerosi

Índice

  1. Artículos de revistas
  2. Tesis
  3. Libros
  4. Capítulos de libros
  5. Actas de conferencias
  6. Informes

Literatura académica sobre el tema "Progressive systemic sclerosi"

Autor: Grafiati
Publicado: 11 de marzo de 2023

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Progressive systemic sclerosi".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Artículos de revistas sobre el tema "Progressive systemic sclerosi"

1

Asherson, R. A., H. Angus, J. A. Mathews, O. Meyers y G. R. Hughes. "The progressive systemic sclerosis/systemic lupus overlap: an unusual clinical progression." Annals of the Rheumatic Diseases 50, n.º 5 (1 de mayo de 1991): 323–27. http://dx.doi.org/10.1136/ard.50.5.323.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Cascone, Piero, Andrea Rivaroli y Stefano Vetrano. "Progressive Systemic Sclerosis". Journal of Craniofacial Surgery 9, n.º 5 (septiembre de 1998): 472–76. http://dx.doi.org/10.1097/00001665-199809000-00018.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Lundborg, Christopher N., Petre V. Nitescu, Lennart K. Appelgren y Ioan D. Curelaru. "Progressive Systemic Sclerosis". Regional Anesthesia and Pain Medicine 24, n.º 1 (enero de 1999): 89–93. http://dx.doi.org/10.1097/00115550-199924010-00016.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Roberts, James G., Raj Sabar, John A. Gianoli y Alan D. Kaye. "Progressive Systemic Sclerosis". Journal of Clinical Anesthesia 14, n.º 6 (septiembre de 2002): 474–77. http://dx.doi.org/10.1016/s0952-8180(02)00380-x.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Fogo, Agnes. "Progressive Systemic Sclerosis". American Journal of Kidney Diseases 34, n.º 2 (agosto de 1999): E4—E5. http://dx.doi.org/10.1053/s0272-6386(13)90019-6.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Ananyeva, L. P., I. E. Tyurin, O. A. Koneva, L. A. Garzanova y A. M. Lila. "Interstitial lung disease in systemic sclerosis (systemic scleroderma)". Modern Rheumatology Journal 15, n.º 1S (17 de marzo de 2021): 1–62. http://dx.doi.org/10.14412/1996-7012-2021-1s-1-62.

Texto completo
Resumen
In systemic sclerosis (SSc), interstitial lung disease (ILD) is common (>80%) and worsens the prognosis of the disease, but severe progressive damage develops only in 8–10% of cases. Interstitial changes in the lungs occur early (within the first 3–5 years of the disease). The histological manifestations are similar to those of idiopathic ILD.The main tool for screening and diagnosing of ILD associated with SSc is high-resolution computed tomography of the lungs, resulting data influence the choice of therapy. In most patients a relatively intact and stable forced vital capacity of the lungs is recorded for a long time, but the diffusion capacity of the lungs decreases early and steadily. Pulmonary functional tests have prognostic value.The choice of the optimal therapy for SSc with lung lesions is based on general disease activity (the severity of inflammation and fibrosis) and the its severity, rate of progression of the disease in general and the leading pathology – interstitial pneumonia (IP) – in particular. In patients with SSc and severe or progressive IP, treatment with mycophenolate mofetil (MMF), cyclophosphamide, nintedanib, or nintedanib in combination with MMF if appropriate, should be considered. If this therapy is ineffective, rituximab may be used.
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Evans, D. J., S. J. Cashman y M. Walport. "PROGRESSIVE SYSTEMIC SCLEROSIS: AUTOIMMUNE ARTERIOPATHY". Lancet 329, n.º 8531 (febrero de 1987): 480–82. http://dx.doi.org/10.1016/s0140-6736(87)92091-5.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Haustein, U. F., K. Herrmann y H. J. Böhme. "Pathogenesis of Progressive Systemic Sclerosis". International Journal of Dermatology 25, n.º 5 (junio de 1986): 286–94. http://dx.doi.org/10.1111/j.1365-4362.1986.tb02244.x.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Bollinger, Alfred. "Microangiopathy of Progressive Systemic Sclerosis". Archives of Internal Medicine 146, n.º 8 (1 de agosto de 1986): 1541. http://dx.doi.org/10.1001/archinte.1986.00360200103017.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Volkmann, Elizabeth R. "Natural history of systemic sclerosis–related interstitial lung disease: How to identify a progressive fibrosing phenotype". Journal of Scleroderma and Related Disorders 5, n.º 2_suppl (5 de diciembre de 2019): 31–40. http://dx.doi.org/10.1177/2397198319889549.

Texto completo
Resumen
The natural history of interstitial lung disease in patients with systemic sclerosis is highly variable. Historical observational studies have demonstrated that the greatest decline in lung function in systemic sclerosis occurs early in the course of the disease; however, not all patients experience a decline in lung function even in the absence of treatment. Furthermore, among patients who do experience a decline in lung function, the rate of decline can be either rapid or slow. The most common clinical phenotypes of systemic sclerosis–related interstitial lung disease are, therefore, as follows: (1) rapid progressors, (2) gradual progressors, (3) stabilizers, and (4) improvers. This review summarizes the features of systemic sclerosis–related interstitial lung disease patients who are more likely to experience rapid progression of interstitial lung disease, as well as those who are more likely not to experience interstitial lung disease progression. Understanding the clinical, biological, and radiographic factors that consistently predict interstitial lung disease–related outcomes in systemic sclerosis is central to our ability to recognize those patients who are at heightened risk for interstitial lung disease progression. With new options available for treating patients with systemic sclerosis–related interstitial lung disease, it is more important than ever to accurately identify patients who may derive the most benefit from aggressive systemic sclerosis–related interstitial lung disease therapy. Early therapeutic intervention in patients with this progressive fibrosing phenotype may ultimately improve morbidity and mortality outcomes in patients with systemic sclerosis–related interstitial lung disease.
Los estilos APA, Harvard, Vancouver, ISO, etc.
Más fuentes

Tesis sobre el tema "Progressive systemic sclerosi"

1

McSwiggan, Stephen John. "Cardiovascular events and mortality in systemic sclerosis : a study of the effect of Iloprost on these and on disease progression : the SSTEP Study (Systemic Sclerosis Trial of Events and Progression)". Thesis, University of Dundee, 2014. https://discovery.dundee.ac.uk/en/studentTheses/163dc6e5-b5dd-4945-9756-8dae629cff48.

Texto completo
Resumen
Background: Systemic sclerosis (SSc) is an autoimmune disease associated with significant mortality and morbidity. Cardiovascular causes are the single largest contributor to premature death. To date, much of the focus on managing the care of SSc patients has concentrated on traditional risk factors related to fibrotic and microvascular dysfunction. There is, however, evidence of a strong cardiovascular component to the disease and points to macrovascular dysfunction as being a key contributor to the premature mortality associated with SSc. This thesis reports on the conduct of a multi-centre, randomised, placebo-controlled clinical trial (the SSTEP Study). The aim of the study was to assess whether oral Iloprost was more effective than placebo in reducing cardiovascular events and disease progression in SSc. Methods: Two hundred and sixteen patients with systemic sclerosis were recruited, between February 2002 and February 2005, at nine centres in the UK and Ireland. After one month placebo run-in, participants were randomised to either oral Iloprost (50-200mcg daily) or matched placebo. Baseline demographics, disease characteristics and organ screening data were collected, and participants were reviewed annually for endpoint measurements; CV events, SSc disease progression and mortality, with regular safety reviews between these annual visits. Participants were followed up for a period of 4 to 7 years. Results: Data analysis of the combination of the two measures (survival free from death or a cardiovascular event) demonstrated a trend towards favouring Iloprost over placebo but the difference was not statistically significant (Logrank test: Chi square=0.75, p=0.39). When time to a confirmed cardiovascular endpoint alone was examined there was a suggestion of a benefit from Iloprost, but the difference was again not statistically significant (Logrank test, Chi square =0.82, p=0.37). There was no statistically significant change in the rate at which organ screening endpoints occurred throughout follow-up, and for each endpoint there was no statistically significant difference between results in patients randomised to Iloprost compared to those randomised to placebo. Withdrawal from the treatment to which the patient was randomised was frequent with 97 (45%) of the total participants discontinuing study medication. ‘On treatment’ analysis, undertaken using the endpoint of death or confirmed cardiovascular endpoint, just failed to show statistical significance at the 5% level (p=0.054). Conclusion: The results of the SSTEP study showed that there was a trend towards favouring oral Iloprost over placebo in systemic sclerosis, though there was no statistically significant evidence to recommend its use to prevent disease progression. The high rate of withdrawal from both Iloprost and placebo hindered the possibility of demonstrating that Iloprost was effective in this study. It cannot be concluded that it is a useful therapy that may prevent premature mortality or progression to cardiovascular disease in this patient group.
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Weigold, Florian [Verfasser]. "Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis / Florian Weigold". Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2018. http://d-nb.info/1176633147/34.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Wang, Ming-Dong. "Identification of Risk Factors Associated with Aetiology of Amyotrophic Lateral Sclerosis Based on Systematic Review and Meta-Analysis". Thèse, Université d'Ottawa / University of Ottawa, 2014. http://hdl.handle.net/10393/31145.

Texto completo
Resumen
To identify the risk factors being associated with aetiology of amyotrophic lateral sclerosis (ALS), a series of systematic reviews based on existing observational epidemiological studies identified through searching of bibliographic databases were conducted. Associations between ALS and a number of genetic and environmental risk factors were examined using meta-analysis. Specifically we found that previous exposure to lead, pesticides, solvents, experience of trauma and electric shock were associated with relative increased risks of developing ALS of 86% [odds ratio (OR) =1.86, 95% CI: 1.39-2.48], 57% (OR=1.57,95% CI: 1.19-2.08), 47% (OR=1.47, 95%CI: 1.13-1.80), 64% (OR=1.64; 95%CI: 1.36-1.98), and 2.27% (OR=3.27, 95%CI:1.87-5.73) respectively, compared to their corresponding controls. The presence of intermediate CAG repeat expansion in the ATXN2 gene was associated with a 4.4 -fold increase in the risk of ALS (OR=4.44, 95%CI: 2.91-6.76). However, the attributable risk associated with each identified risk factor was estimated to be less than 5% of all ALS cases. These results confirm that ALS is a rare multifactorial degenerative condition of motor-neurons.
Los estilos APA, Harvard, Vancouver, ISO, etc.

Libros sobre el tema "Progressive systemic sclerosi"

1

Coyle, Patricia K. Living with progressive mulitple sclerosis: Overcoming the challenges. 2a ed. New York, NY: Demos Medical Pub., 2008.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Current issues in clinical neurovirology: Pathogenesis, diagnosis and treatment. Philadelphia, Pa: Saunders, 2008.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Black, Carol M. Progressive Systemic Sclerosis (Current Topics in Rheumatology). Gower Medical Pub, 1985.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Progressive Multiple Sclerosis: New Hope, New Challenges. Demos Medical Publishing, 2007.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Bhargava, Pavan y Shiv Saidha. Multiple Sclerosis: Monitoring Disease Activity and Progression. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0084.

Texto completo
Resumen
Multiple sclerosis is a chronic inflammatory and degenerative disorder of the central nervous system. Measuring disease activity and progression are an integral part of the management of the disorder. A number of different approaches, including clinical measures, imaging metrics, and blood/cerebrospinal fluid biomarkers have been investigated for their utility in monitoring disease activity and progression. Each of these different approaches has certain advantages, as well as limitations, and this chapter provides an overview of these different assessment strategies.
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Esch, Megan y Nancy L. Sicotte. Neuroimaging in Multiple Sclerosis. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199341016.003.0007.

Texto completo
Resumen
Magnetic resonance imaging (MRI) of the brain and spinal cord plays an integral role in establishing the diagnosis of multiple sclerosis (MS). The use of MRI leads to earlier recognition of MS, allowing for earlier treatment initiation and more efficient monitoring of disease treatment and progress. This chapter outlines conventional MRI imaging sequences that are used to evaluate MS white matter lesions in the central nervous system. It also addresses the incorporation of new imaging techniques that have increased understanding of clinically definite MS, its variants, and how various diseases can mimic traditional MS. Finally, it examines novel imaging protocols that have been implemented in MS research, which have elucidated radiographic and pathophysiologic nuances and involvement of deeper central nervous system structures and tracts that play a role in MS progression.
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Watson, Max, Caroline Lucas, Andrew Hoy y Jo Wells. Palliative care in non-malignant neurological disease. Oxford University Press, 2010. http://dx.doi.org/10.1093/med/9780199234356.003.0029.

Texto completo
Resumen
This chapter focuses on the symptom management of multiple sclerosis, Parkinson’s disease, multiple system atrophy (MSA), progressive supranuclear palsy (PSP), motor neuron disease, neurological complications of AIDS, Creutzfeldt-Jakob disease (CJD), and useful contacts.
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Shaw, Pamela. The motor neurone disorders. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780198569381.003.0524.

Texto completo
Resumen
The motor neurone diseases are a group of disorders in which there is selective loss of function of upper and/or lower motor neurones in the motor cortex, brainstem, and spinal cord resulting in impairment in the nervous system control of voluntary movement. The term ‘motor neurone disease’, often abbreviated to ‘MND’, is used differently in different countries. In the United Kingdom it is used as an umbrella term to cover the related group of neurodegenerative disorders including amyotrophic lateral sclerosis, the commonest variant, as well as progressive muscular atrophy, primary lateral sclerosis, and progressive bulbar palsy. However, in many other countries amyotrophic lateral sclerosis, referred to as ALS, has been adopted as the umbrella term for this group of clinical variants of motor system degeneration. There is a tendency now internationally to use the ALS/MND abbreviation to cover this group of conditions. Careful diagnosis within the motor neurone diseases is essential for advising about prognosis, potential genetic implications, and for identifying those with acquired lower motor neurone syndromes who may benefit for the administration of immunomodulatory therapy.
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Guo, Yong y Claudia F. Lucchinetti. Taking a Microscopic Look at Multiple Sclerosis. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199341016.003.0005.

Texto completo
Resumen
The pathology of multiple sclerosis is complex, extends beyond the white matter plaque, and is influenced by stage of demyelinating activity, clinical course, disease duration, and treatment. Technological advances in immunology, molecular biology, and “omic” biology have provided novel insights into the mechanisms for development of white matter plaques, axonal damage, cortical demyelination, and disease progression. Detailed, systematic, and statistically rigorous pathological studies on clinically well-characterized MS cohorts have helped define the heterogeneous pathological substrates of MS and unravel the complex molecular pathogenic mechanisms, with the ultimate goal of identifying targets for therapeutic interventions. It is increasingly clear that the use of human tissues is imperative to improve current diagnostic, prognostic, and therapeutic modalities. Preclinical animal models have been invaluable for discovery of key immune processes, basic disease mechanisms, and candidate immune targeting strategies, but the conclusions have yet be reconciled with the essential features of the human disease.
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Eve, Adamson, ed. The Wahls protocol: How I beat progressive MS using Paleo principles and functional medicine. 2014.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
Más fuentes

Capítulos de libros sobre el tema "Progressive systemic sclerosi"

1

Müller, Rüdiger y Johannes von Kempis. "Progressive Systemic Sclerosis". En Clinical Trials in Rheumatology, 473–524. London: Springer London, 2010. http://dx.doi.org/10.1007/978-1-84996-384-8_6.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Müller, Rüdiger y Johannes von Kempis. "Progressive Systemic Sclerosis". En Clinical Trials in Rheumatology, 849–917. London: Springer London, 2012. http://dx.doi.org/10.1007/978-1-4471-2870-0_6.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Knop, J. y G. Bonsmann. "Ciclosporin in the Treatment of Progressive Systemic Sclerosis". En Ciclosporin in Autoimmune Diseases, 199–200. Berlin, Heidelberg: Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-642-70607-3_37.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Tzioufas, Athanasios G., Georgia Liantinioti y Panayotis G. Vlachoyiannopoulos. "Sjogren’s Syndrome (Ss) in Progressive Systemic Sclerosis (SSc)". En In Clinical Practice, 281–97. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-53736-4_23.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Schiopu, Elena y James R. Seibold. "Rapidly Progressive Skin Disease in a Patient with Diffuse Systemic Sclerosis". En Case Studies in Systemic Sclerosis, 107–14. London: Springer London, 2011. http://dx.doi.org/10.1007/978-0-85729-641-2_11.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Condliffe, Robin. "Disease Progression in Systemic Sclerosis Associated Pulmonary Arterial Hypertension". En Advances in Vascular Medicine, 289–303. London: Springer London, 2009. http://dx.doi.org/10.1007/978-1-84882-637-3_17.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Tyndall, Alan G. "A 34-Year-Old Woman with 2-Year History of Therapy-Resistant, Rapidly Progressive SSc Successfully Treated by Autologous Hematopoietic Stem Cell Transplantation". En Case Studies in Systemic Sclerosis, 331–37. London: Springer London, 2011. http://dx.doi.org/10.1007/978-0-85729-641-2_34.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Miyachi, K., T. Mimori, S. Takano, H. Yamagata, Y. Matsuoka, S. Irimajiri, K. Tani, M. Akizuki y M. Homma. "Further Characterization of the Anti-Wa Antibody to a tRNA-Related Protein in Progressive Systemic Sclerosis". En Molecular and Cell Biology of Autoantibodies and Autoimmunity. Abstracts, 56–57. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-46681-6_48.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Gates, Nathan A., Christopher K. Hauser y Eric W. Sellers. "A Longitudinal Study of P300 Brain-Computer Interface and Progression of Amyotrophic Lateral Sclerosis". En Foundations of Augmented Cognition. Directing the Future of Adaptive Systems, 475–83. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-21852-1_54.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

"Progressive Systemic Sclerosis". En Diagnostic Imaging: Musculoskeletal Non-Traumatic Disease, 884–87. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-323-39252-5.50237-7.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.

Actas de conferencias sobre el tema "Progressive systemic sclerosi"

1

Pozzolo, Roberto Dal, Alessandra Meneghel, Biagio Castaldi, Giovanni Civieri, Giorgia Martini, Renzo Marcolongo, Alida Linda Patrizia Caforio y Francesco Zulian. "THU0532 RITUXIMAB FOR RAPIDLY PROGRESSIVE JUVENILE SYSTEMIC SCLEROSIS". En Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.7377.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Huang, W. N., Y. M. Chen, W. T. Hung, C. W. Hsieh, C. T. Lin y Y. H. Chen. "AB0817 Prominent nailfold capillary avascular area predicts malignancy in progressive systemic sclerosis". En Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.6517.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Hoffmann-Vold, Anna-Maria, Yannick Allanore, Margarida Alves, Nicole Graf, Paolo Airò, Lidia P. Ananyeva, László Czirják et al. "Disease course and outcome of progressive interstitial lung disease in systemic sclerosis". En ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.oa3598.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Carvalho Inacio de Vasconcellos, Caio, Maria Cecilia da Fonseca Salgado, Ana Paula Casseta Nucera, Alessandra Cardoso Pereira, Camila Souto, Felipe Cesar Freire y João Luiz Pereira Vaz. "SYSTEMIC SCLEROSIS WITH SEVERE AND RAPIDLY PROGRESSIVE MYOCARDIAL FIBROSIS: A CASE REPORT". En Congresso Brasileiro de Reumatologia 2020. Sociedade Brasileira de Reumatologia, 2021. http://dx.doi.org/10.47660/cbr.2020.17251.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Bély, M., T. Szentjóbi Szabó, P. Kapp, Á. Apáthy, M. Stancikova y R. Istok. "AB0108 Complications and formal pathogenesis of progressive systemic sclerosis. a retrospective study". En Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.256.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Dobrota, R., S. Jordan, P. Juhl, B. Maurer, L. Wildi, A.-C. Bay-Jensen, MA Karsdal, AS Siebuhr y O. Distler. "FRI0365 New collagen biomarkers predict progression of fibrosis in systemic sclerosis". En Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.4909.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Apáthy, Ά. y M. Bély. "AB0164 Amyloidosis in progressive systemic sclerosis – a postmortem clinicopathologic study of 12 patients". En Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.1226.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Hoffmann-Vold, A. M., C. Brunborg, P. Airò, L. P. Ananyeva, L. Czirják, S. Guiducci, E. Hachulla et al. "Cohort enrichment strategies for progressive interstitial lung disease in systemic sclerosis from EUSTAR". En ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.1100.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Leeuwen, Nina van, Maaike Boonstra, Jaap Bakker, Corrie Wortel, Hans Ulrich Scherer, Rene Toes, Thomas Huizinga y Jeska de Vries-Bouwstra. "AB1299 AN ONGOING ANTICENTROMERE ANTIBODY RESPONSE ASSOCIATES WITH PROGRESSION TOWARDS SYSTEMIC SCLEROSIS". En Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.3029.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Lorenzis, Enrico De, Gerlando Natalello, Laura Gigante, Lucrezia Verardi, Umberto La Porta, Giovanni Battista Canestrari, Ludovica Berardini, Silvia Laura Bosello y Elisa Gremese. "FRI0319 ESOPHAGEAL EROSIONS PREDICT PROGRESSION OF LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS". En Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.6401.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.

Informes sobre el tema "Progressive systemic sclerosi"

1

Wu, Xin. The efficacy and safety of anti-CD20 antibody treatments in relapsing multiple sclerosis: a systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, junio de 2022. http://dx.doi.org/10.37766/inplasy2022.6.0075.

Texto completo
Resumen
Review question / Objective: The objectives of this systematic review were to evaluate the efficacy and safety of the three existing anti-CD20 antibodies for the treatment of relapsing multiple sclerosis and to aid clinicians in choosing medications. Eligibility criteria: We set the inclusion criteria as follows: (1) study type: RCT; (2) language restriction: only available in English; (3) participants: patients ≥18 years of age diagnosed with relapsing MS, whether with a relapsing–remitting course or a secondary progressive course; (4) intervention: anti-CD20 antibody treatments including ocrelizumab, ofatumumab, rituximab, and corresponding control including placebo and active treatments; (5) outcomes: clinical outcomes including annualized rate of relapse (ARR), the number of patients free of relapse, and the number of patients with confirmed disease progression (CDP); magnetic resonance imaging(MRI) outcomes including gadolinium-enhancing lesion change in T1, change in the volume of lesions on T2, the number of patients with no new or newly enlarged lesions in T2 and the brain volume change (BVC); safety outcomes including adverse events (AEs) and serious adverse events (SAEs). Included RCTs were not requested to supply all the outcomes mentioned above. We set the exclusion criteria as follows: (1) study type: retrospective studies, cohort studies, case reviews and case reports; (2) patients diagnosed with primary progressive MS.
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Timm, Eliane, Julia Vieregg y Ursula Wolf. Movement based mindfulness therapies in patients with multiple sclerosis – a systematic review protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, febrero de 2022. http://dx.doi.org/10.37766/inplasy2022.2.0102.

Texto completo
Resumen
Review question / Objective: The aim is to review the clinical benefits of mindful moving techniques for persons with multiple sclerosis. Condition being studied: Multiple sclerosis. Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system (Gholamzad et al., 2019; Oh, Vidal-Jordana, & Montalban, 2018). It has shown to be increasing since 2013, and as of 2020 the estimated number of people with MS is 2.8 million worldwide (Walton et al., 2020). Due accumulation of relapses or gradual progression, disability from MS is worsening over time (Cameron & Nilsagard, 2018), which results in common symptoms like pain, imbalance, weakness, motor disorders, fatigue, depression, and more (Cameron & Nilsagard, 2018; Guicciardi et al., 2019).
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Zhu, Qiaochu, Jin Zhou, Hai Huang, Jie Han, Biwei Cao, Dandan Xu, Yan Zhao y Gang Chen. Risk factors associated with amyotrophic lateral sclerosis: a protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, septiembre de 2022. http://dx.doi.org/10.37766/inplasy2022.9.0118.

Texto completo
Resumen
Review question / Objective: To identify and list the risk factors associated with the onset and progression of ALS. Condition being studied: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting the upper and lower motor neurons in the spinal bulb, cerebral cortex, and spinal cord. The clinical processing symptoms accompany muscle atrophy, fasciculation, and fatigue of limbs, which can lead to general paralysis and death from respiratory failure within 3-5 years after the onset of this disease. Though the pathogenesis of ALS is still unclear, exploring the associations between risk factors and ALS can provide reliable evidence to find the pathogenesis in the future. This meta-analysis aims to synthesize all related risk factors on ALS, comprehensively understand this disease, and provide clues to mechanism research and clinicians.
Los estilos APA, Harvard, Vancouver, ISO, etc.
También puede estar interesado en las bibliografías ampliadas sobre el tema "Progressive systemic sclerosi" para tipos de fuentes particulares:
Artículos de revistas Libros
Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!

Pasar a la bibliografía